Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2889-2895

  Burstein, Harold J ^a   Harris, Lyndsay N ^a   Marcom, P Kelly ^a   Lambert Falls, Rosemary ^a   Havlin, Kathleen ^a   Overmoyer, Beth ^a   Friedlander Jr , Robert J ^a   Gargiulo, Janet ^a   Strenger, Rochelle ^a   Vogel, Charles L ^a   Ryan, Paula D ^a   Ellis, Mathew J ^a   Nunes, Raquel A ^a   Bunnell, Craig A ^a   Campos, Susana M ^a   Hallor, Michele ^a   Gelman, Rebecca ^a   Winer, Eric P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VINBLASTINE;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; ADULT; AGED; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; HEART DISEASE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; ROC CURVE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEART DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 0041885349     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.018     Document Type: Article

References (19)

1. McKeage K, Perry CM. Trastuzumab. Drugs 62:209-243, 2002
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
4. Pegram MD, Lopez A, Konecny G, et al: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27:21-25, 2000 (6 suppl 11)
5. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
6. Domenech GH, Vogel CL: A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2:113-128, 2001
7. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
8. Mass RD, Press M, Anderson S, et al: Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20:22a 2001; (abstr 85)
9. Nunes RA, Harris LN: The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 3:125-135, 2002
10. Anderson TI, Paus E, Nesland JM, et al: Detection of c-erbB-2 related protein in sera from breast cancer patients: Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 34:499-504, 1995
11. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:26-36, 1982
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
13. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
14. Fountzila G, Tsavdaridid D, Kalogera-Fountzila A, et al: Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 12:1545-1551, 2001
15. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing meta-static breast cancer. J Clin Oncol 20:1800-1808, 2002
16. Jahanzeb M, Mortimer J, Yunus F, et al: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 7:410-417, 2002
17. Nabholtz MJ, Pienkowski T, Nothfelt D, et al: Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) as therapy for advanced breast cancer in women with tumors over-expressing the HER2-neu protooncogene. Eur J Cancer37:190, 2001(abstr 695, suppl 6)
18. Robert N, Leyland-Jones B, Asmar L, et al: Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 76:S37, 2002 (abstr 35, suppl 1)
19. Burstein HJ, Bunnell CA, Winer EP: New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol 28:344-358, 2001